RareSearch logo

The Wistar Institute Proteomics Facility

50+ personnel
Headquartered in Chandler
Established in 2025
Website
Catherine Graham profile

Catherine Graham

🇬🇧 United Kingdom

8.9

    Reviewed:

  • - Stability Studies
  • - 18 months January 2023 - June 2024
  • - Pharmaceutical Company

Accurate and reliable stability studies, clear reporting.

The stability studies were conducted with precision, and the reporting was clear and thorough. The results provided us with the necessary data to proceed with our regulatory submissions confidently.

Earl Hand V profile

Earl Hand V

🇫🇷 France

5.8

    Reviewed:

  • - Biostatistical Design
  • - 6 weeks February - March 2024
  • - Research Institution

Biostatistical analysis lacked depth, missed key insights.

The biostatistical analysis provided was not as thorough as we had hoped. Some key insights were missed, and we had to engage another provider to get the level of detail we needed. The team seemed overworked and under-resourced.

Nadine Upton profile

Nadine Upton

🇩🇪 Germany

9.3

    Reviewed:

  • - Market Access Strategy
  • - 6 weeks January - February 2024
  • - Pharmaceutical Company

Strategic market access analysis, insightful recommendations.

The market access analysis provided strategic insights that were crucial to our launch strategy. The team's recommendations were data-driven and actionable, helping us to make informed decisions.

Luz Wisoky-Beahan profile

Luz Wisoky-Beahan

🇷🇺 Russia

9.2

    Reviewed:

  • - Data Visualization
  • - 3 weeks December 2023
  • - Pharmaceutical Company

Highly effective data visualization, easy to interpret and impactful.

The data visualization services were highly effective, making complex data easy to interpret and communicate. The visualizations were impactful and played a crucial role in our stakeholder presentations.

Clarence Beatty profile

Clarence Beatty

🇺🇸 United States

6

    Reviewed:

  • - Health Technology Assessment
  • - 8 weeks July - September 2024
  • - Pharmaceutical Company

Health technology assessment was superficial, lacked thorough analysis.

The health technology assessment (HTA) was superficial and did not provide the level of thorough analysis we needed. Some important factors were overlooked, and we had to request additional work to cover these gaps. The overall experience was disappointing.

Elijah Grady profile

Elijah Grady

🇮🇹 Italy

9.1

    Reviewed:

  • - HTA Submission
  • - 8 weeks February - March 2024
  • - Biotech Company

Comprehensive and well-executed HTA submission.

The HTA submission was comprehensive and well-executed. The team managed the complexities of the submission process expertly, ensuring that all necessary data was included and well-presented.

Bessie Howell DVM profile

Bessie Howell DVM

🇩🇪 Germany

9.3

    Reviewed:

  • - Project Management
  • - 10 weeks July - September 2023
  • - Biotech Company

Seamless project management, results exceeded expectations.

Project management was seamless, and the team exceeded our expectations. They handled all aspects of the project with professionalism and efficiency, keeping us informed every step of the way.

Ellen Schmitt profile

Ellen Schmitt

🇳🇱 Netherlands

8.9

    Reviewed:

  • - Medical Writing
  • - 5 weeks October - November 2023
  • - Biotech Company

Top-quality medical writing, clear and precise documents.

The medical writing services provided were of top quality. The documents were clear, precise, and tailored to meet the specific requirements of our regulatory submissions. The team's expertise was evident throughout the process.

Frankie Hartmann profile

Frankie Hartmann

🇫🇷 France

8.9

    Reviewed:

  • - Regulatory Submission
  • - 6 weeks February 2023
  • - Biotech Startup

Professional and knowledgeable, seamless regulatory submission process.

Our regulatory submission was handled with great care and expertise. The process was seamless, and their knowledge of the regulatory landscape was impressive. The team's support was invaluable, and I would not hesitate to use their services again.